Tegoprazan
- Generic Name
- Tegoprazan
- Drug Type
- Small Molecule
- Chemical Formula
- C20H19F2N3O3
- CAS Number
- 942195-55-3
- Unique Ingredient Identifier
- W017G7IF4S
- Background
Tegoprazan (also known as CJ-12420) is a novel therapeutic developed by CJ Healthcare Corp for treating acid-related gastrointestinal diseases. This drug is a potent and high-selective potassium-competitive acid blocker (P-CAB) with a fast onset of action and the ability to control gastric pH for a prolonged period of time. Tegoprazan’s strong and sustained effect is due to its ability to be slowly cleared from the gastric glands and exertion of effects independent of acid levels. It has also been observed to be efficacious independent of food intake.
- Indication
用于治疗胃食管反流病、糜烂性食管炎及消化性溃疡等酸相关疾病。
HK inno.N's K-CAB Poised for Indian Market Entry Following Positive Recommendation
• HK inno.N's K-CAB, a GERD treatment, received a positive recommendation from India's Subject Expert Committee (SEC) for both 25 mg and 50 mg dosages.
• The 50 mg tablet is recommended for erosive and non-erosive GERD and gastric ulcers, while the 25 mg tablet is for maintenance therapy post-erosive GERD treatment.
• K-CAB, a potassium-competitive acid blocker (P-CAB), is already available in 46 countries and has shown rapid action and long-term efficacy.
• With India being the fourth-largest market for peptic ulcer drugs, K-CAB's potential approval could significantly expand its global impact.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath